

CLINICAL SCIENCE

Helicobacter pylori as a potential target for the treatment of central serous chorioretinopathy

Antonio Marcelo Barbante Casella,^I Rodrigo Fabri Berbel,^I Gláucio Luciano Bressanim,^{II} Marcus Rudolph Malaguido,^I José Augusto Cardillo^{III}

^I Universidade Estadual de Londrina, Department of Ophthalmology, Londrina, Brazil. ^{II} Instituto da Visão de Cascavel, Department of Ophthalmology, Cascavel, Brazil. ^{III} Hospital de Olhos de Araraquara, Department of Ophthalmology, Araraquara, Brazil.

OBJECTIVES: The objective of this study was to evaluate the relationship between the treatment of *Helicobacter pylori* gastric infection and changes in best-corrected visual acuity and macular detachment in patients with chronic central serous chorioretinopathy.

METHODS: Seventeen patients diagnosed with central serous chorioretinopathy were examined for gastric infection with *Helicobacter pylori* using the urease test and gastric biopsy. *Helicobacter pylori*-positive patients were treated with the appropriate medication. The response to therapy was monitored by evaluating the best-corrected visual acuity and optical coherence tomography. The data were analyzed using Student's t-test before and after treatment.

RESULTS: Fourteen patients (15 eyes) aged 30-56 years (mean 43.4 ± 8.3 years) were positive for *Helicobacter pylori*. Most of the positive patients had gastric symptoms (78.5%); one had bilateral central serous chorioretinopathy. The mean baseline best-corrected visual acuity was 20/98 (logMAR = 0.53 ± 0.28). Three months after starting treatment with antibiotics, the serous detachment had resolved in 14 of 15 eyes, but two cases required laser treatment. The follow-up period ranged from 6 to 27 months. The mean final best-corrected visual acuity differed significantly from baseline.

CONCLUSION: Our findings suggest that *Helicobacter pylori* infection may be present in many chronic central serous chorioretinopathy patients and that treatment for the infection may have a favorable effect on the outcome of chronic central serous chorioretinopathy. Due to the possibility of the spontaneous regression of chronic central serous chorioretinopathy and the high prevalence of the infection in the general population, prospective and masked clinical trials are necessary to confirm that treatment for *Helicobacter pylori* infection may benefit patients with chronic central serous chorioretinopathy.

KEYWORDS: Risk Factors; Central Serous Chorioretinopathy; *Helicobacter Pylori*; Treatment; Macula.

Casella AM, Berbel RF, Bressanim GL, Malaguido MR, Cardillo JA. *Helicobacter pylori* as a potential target for the treatment of central serous chorioretinopathy. Clinics. 2012;67(9):1047-1052.

Received for publication on May 1, 2012; First review completed on May 17, 2012; Accepted for publication on May 17, 2012

E-mail: mcasella@sercomtel.com.br

Tel.: 55 43 3324-1177

INTRODUCTION

Central serous chorioretinopathy (CSC) causes a serous neurosensory detachment of the macula associated with one or more idiopathic leaks at the level of the retinal pigment epithelium (RPE). It predominantly affects male adults aged 40-60 years (1,2). Although the condition spontaneously improves in at least 90% of those affected, recurrence affects approximately one third of patients (3). Among patients with CSC, the chronic form of central serous chorioretinopathy (CCSC) is defined as the repeating variant of the

disease or diffuse retinal pigment epitheliopathy for more than six months (4,5). These patients are difficult to treat, with the most successful modality appearing to be photodynamic therapy (PDT) guided by optical coherence tomography (OCT). However, patients may lose vision due to atrophic changes in the RPE/photoreceptor layer (5).

The potential risk factors for CSC include hypertension, pregnancy, allergic respiratory disease, antibiotic or alcohol use, corticosteroid therapy and sympathomimetic drugs (1,2,6-8). A correlation between CSC and infection with *Helicobacter pylori* (HP) was recently suggested (9-15). In a prospective pilot study of 16 patients with CSC and diffuse retinal pigment epitheliopathy, the prevalence of *Helicobacter pylori* infection was significantly higher in patients with CSC than in the general population (10). The prevalence was also significantly higher in CSC patients than in a control population from the same country (11). Other studies also demonstrated this correlation (14,15). One recent article

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

No potential conflict of interest was reported.

found good outcomes in patients with CSC and receiving treatment for HP eradication therapy (16). Thus, the objective of the present study was to assess the best-corrected visual acuity (BCVA) and macular detachment using OCT in patients with CCSC who were receiving conventional drug therapy to treat HP infection.

MATERIALS AND METHODS

This was an interventional, non-blinded case series of patients with proven chronic CSC. The study was approved by the research ethics committee of the State University of Londrina, and all patients provided informed written consent. CSC was defined as an idiopathic leakage at the level of the retinal pigment epithelium leading to the accumulation of subretinal fluid. Subjects diagnosed with long-lasting (>6 months) or recurring (2 or more times over the preceding 12 months) CSC and serous macular detachment involving the fovea were followed by the authors from September 2003 to November 2008. Twenty patients were invited to participate in the study, but only 17 accepted. None of the subjects used corticosteroids or sympathomimetic drugs or had a systemic disease associated with CSC.

The patients had a complete ophthalmological examination, including best-corrected Snellen visual acuity (BCVA), slit-lamp biomicroscopy, tonometry, indirect binocular ophthalmoscopy, optical coherence tomography (time domain OCT: Stratus OCT-3000; Carl Zeiss Meditec, Dublin, CA, USA) and, in the absence of confirmed or suspected allergy and clinical contraindication, fluorescein angiography. Patients with clinically and image-confirmed serous detachment were asked about gastric symptoms and referred for HP screening with urease tests and gastric biopsy by endoscopy when the urease test was negative (17).

HP-positive patients were treated with a combination of clarithromycin (500 mg twice a day), amoxicillin (1 g twice a day) and lansoprazole (30 mg twice a day) for seven days. The treatment was prescribed and followed by a gastroenterologist who performed the endoscopic examination of the upper digestive tract. Following drug therapy, patients underwent complete ophthalmological examinations at 30-day intervals to assess visual acuity and ocular status. OCT images were used to assess the resolution of disease (absence of subretinal fluid). The follow-up period ranged from 6 to 27 months. A second endoscopic examination and gastric biopsy was performed three months after drug therapy to confirm the eradication of the bacteria. Follow-up was continued through November 30, 2008, or ended when the patient decided to undergo another treatment. The variables are presented in a descriptive form. Student's paired t test was used to compare the baseline and end-point BCVA values, and p -values < 0.05 were considered to be statistically significant.

RESULTS

The study population consisted of three women and 14 men. Eighteen eyes of 17 patients, aged 30-56 years (mean: 43.4 ± 8.7 years), were studied. The follow-up period varied from six to 27 months (mean 15 ± 8.1 months). Fifteen eyes tested positive for HP. Table 1 shows the patients according to age, gender, the affected eye, disease duration, the presence of gastric symptoms, HP examination and visual acuity at baseline and after treatment. One case (Case 2) presented with bilateral CCSC. In four patients, serous detachment recurred (Cases 1, 8, 11 and 14).

Case 1 had CCSC in one eye that occurred in September 2003. After HP detection, antibiotic treatment was started, and the serous detachment resolved completely after two

Table 1 - The results of the follow-up of 17 patients (18 eyes) diagnosed with central serous chorioretinopathy (CSC) who were screened and treated for gastric infection with *Helicobacter pylori* (HP).

Patient	Gender	Age (years)	Eye	Duration of disease (months)	Gastric Symptoms	Test for H. pylori	Baseline BCVA	Last follow-up BCVA*	Duration of follow-up (months)
1	M	56	L	36	+	+	20/40	20/30	27 ‡
2	M	46	L	13	+	+	20/80	20/50	27
2	M	46	R	6 (multiple recurrences)	+	+	20/200	20/30	27
3	M	56	L	6 (recurrence at 3 months)	+	+	20/80	20/20	27
4	M	42	R	6	+	+	20/30	20/20	19
5	M	42	R	6	+	+	20/80	20/20	13
6	M	31	L	12	-	+	20/50	20/50	13**
7	F	50	R	6	+	+	20/100	20/30	13
8	M	43	L	6	+	+	20/30	20/20	12‡
9	M	36	R	6	+	+	20/50	20/20	9
10	M	45	R	36	+	+	20/200	20/80	9
11	M	30	R	6 (recurrence at 3 months)	-	+	20/40	20/25	9††
12	M	37	R	6	-	+	20/60	20/25	9
13	M	55	R	6	+	+	20/40	20/25	6
14	M	37	L	6 (recurrence at 3 months)	+	+	20/400	20/25	6‡‡
15	F	45	R	6	-	-	20/30	20/30	---
16	M	40	L	6	-	-	20/50	20/50	---
17	F	43	L	6 (recurrence at 3 months)	-	-	20/80	20/20	---

*The baseline visual acuity was 20/98 (logMAR = 0.53 standard deviation \pm 0.28); the final visual acuity was 20/31 (log MAR 0.16 \pm 0.17)

†($p = 0.001$) paired Student's t test (for patients 1-14)

‡Recurrence with serous detachment. Second biopsy positive. Retreated with improvement of serous detachment.

**Persistent serous detachment treated with laser photocoagulation

††Recurrence after anti-HP drug therapy and a negative gastric biopsy for HP. Patient treated with laser photocoagulation.

‡‡Recurrence three months after successful treatment with anti-HP drug therapy. The second biopsy was HP positive, but the patient requested to be treated with both anti-HP medication and photodynamic therapy.

months (Figure 1). This patient experienced a recurrence after 20 months and again tested positive for HP. After retreatment, the serous detachment resolved. Case 3 was positive for HP after the first treatment and underwent retreatment. The patient experienced a complete resolution of the serous detachment one month after the treatment ended. All of the other patients experienced resolution of their serous detachment after the first month of treatment except Case 6, who required laser photocoagulation. Case 2 had bilateral serous detachment but no recurrence during the 27 months of follow-up (Figure 2). Case 4 (Figure 3), Case 5 (Figure 4), Case 13 and Case 14 had leaks near the fovea, precluding regular laser treatment. Case 6, despite testing positive for HP, did not improve after antibiotic treatment and was referred for laser photocoagulation of the leakage site. Case 11 experienced complete resolution of the serous detachment after treatment with antibiotics but experienced a CSC recurrence two months later. The gastric biopsy was negative for HP, and the patient was treated with laser coagulation. Case 9 experienced a serous detachment recurrence seven months after successful treatment and was subsequently found to have HP infection. The serous detachment resolved after HP retreatment, and the patient's

visual acuity improved from 20/40 to 20/20. In Case 14, the serous detachment resolved but recurred after five months. The second biopsy was HP positive, but the patient requested treatment with both anti-HP medication and photodynamic therapy, which was successful. The mean baseline visual acuity was 20/98 ($\log\text{MAR}=0.57\pm0.28$). The mean final visual acuity was 20/31 ($\log\text{MAR } 0.16\pm0.17$) and differed significantly from baseline ($p<0.001$).

DISCUSSION

To our knowledge, this is the first study in the literature that treated HP in chronic cases of CSC and reported improvement following an evaluation of BCVA and an OCT examination. A similar study was performed in 2002 (10); however, in that study, HP was not eradicated, the sample size (16 eyes) was smaller than the current study (18 eyes), and improvements in BCVA and OCT were not evaluated.

A French study found HP to be significantly more prevalent in patients diagnosed with CSC than in the normal population (11). In our study, a higher incidence of *Helicobacter pylori* infection (82.35% - 15 patients and 18 eyes) was found than the previously reported prevalence in southern Brazil (63%) (18,19). Interestingly, 13 of 14 patients showed improvement of CCSC following treatment for HP. However, one of these cases recurred, and laser photocoagulation was required after a negative gastric biopsy. In three patients, CCSC recurrence was associated with the recurrence of HP infection, and serous detachment resolved upon anti-HP retreatment in two of the cases; in the third case, the patient asked for both photodynamic therapy and anti-HP medication. In most of the responding cases, serous detachment resolved within one month after antibiotic treatment. One previously reported case of CCSC improved clinically when the gastric infection was eradicated, and recurrences of CCSC in this patient were associated with the return of the bacterial infection (9). The recurrence rate of 27% (5 of 18 eyes) indicates that it is a frequent problem associated with CSC, and this has been previously reported (3,5).

Recently, a decrease in the subretinal fluid reabsorption time was demonstrated in a group that received anti-HP treatment compared to a control group (16).

HP chronically infects the gastric mucosa of more than half of the human population (20). However, only 10-20% of HP-infected patients develop known gastrointestinal complications, such as peptic ulcer, gastric cancer and MALT lymphoma, during their lifetime (21). The clinical outcome of HP infection is determined by a complex interaction between the bacterium and the host (22). HP has also been associated with extra-gastric disorders, including a strong association with idiopathic thrombocytopenic purpura and, to a lesser degree, iron deficiency anemia, cardiovascular disease and atherosclerosis (23). The explanations proposed for these observed associations involve one or more mechanisms with direct pathogenic effects, including molecular mimicry between host and *Helicobacter pylori* antigens, the chronic release of inflammatory mediators, malabsorption and the abnormal production of vasoactive substances (20). Indeed, *Helicobacter pylori* infection may alter vascular function by increasing endothelin 1, inducible nitric oxide synthase and nitric oxide, which may affect a condition such as CSC (24,25). Although all of these data suggest that HP infection is a systemic disease, we found




Figure 1 - Serous detachment in the macular region (A) that was suggestive of CSC and subsequently confirmed with OCT (B). Diffuse hyperfluorescent spots in the macular region and a number of leaks were observed upon fluorescein angiography imaging (C-D). Fundoscopy (E) and OCT imaging (F) indicated resolution of the serous detachment. The macular leaks were found to be diminished using fluorescein angiography, but the hyperfluorescent spots persisted (G-H).




Figure 2 - Fundoscopy demonstrated serous detachment in the lower temporal region (A) of the left eye near the vascular arch and just below the fovea, although the detachment was better observed using OCT (B). Fluorescein angiography showed peripapillary hyperfluorescence (C-D). The serous detachment improved after anti-HP treatment, and the leaks were found to be diminished (E-H). Fundoscopy revealed serous detachment in the papillomacular bundle of the right eye (I). Serous detachment was observed using OCT from the nasal region to the fovea of the right eye (J). Fluorescein angiography showed peripapillary hyperfluorescence (K-L). Serous detachment improved after anti-HP treatment, and the leaks were found to be diminished (M-P).

only one case with bilateral CCSC among HP-positive patients. However, if we were to evaluate angiogram abnormalities in the contralateral eye, they would be present in a significant percentage of patients (3). Another hypothesis is that the medications used to treat HP infection interfere with cortisol metabolism; for example, a decrease in systemic cortisol levels was found after the use of clarithromycin (26). One interesting finding of this research is that 78.5% of the HP-positive patients and 64.7% of all patients had gastric symptoms. This was previously noted by other authors but was not observed in other studies (1,2,6-13,27).

We evaluated the initial BCVA, final BCVA and complete resolution of fluid by OCT and fluorescein angiography. The OCT examination is particularly important in CCSC cases because RPE and photoreceptors may be damaged, and BCVA may not be the best parameter to evaluate the possible benefits of HP treatment, as stated by other authors (28).

This study was limited by its design. The retrospective analysis of a multifactorial condition with a considerable potential for spontaneous resolution, such as CCSC, is problematic. Additionally, the high prevalence of HP infection in the general population is another potential confounding factor to be considered in a retrospective study with a lack of controls. The observed changes in the macular pathology may simply be due to chance or placebo effects or

even indirectly to changes in the emotions of the patients with HP infection. However, the natural history of CCSC observed in practice is different from that reported in this study. Additionally, our findings suggest the possibility that HP infection plays a role in the outcome of patients with CCSC: serous detachment generally improved shortly after initiating HP eradication treatment; the recurrence of CCSC often coincided with the recurrence of HP infection; and the retreatment of recurrent infection led to the resolution of recurrent serous detachment.

Our findings suggest that HP infection may be present in many CCSC patients and that eradication therapy may have a favorable effect on the outcome of the disease. Due to the multifactorial causes of CCSC, the possibility of spontaneous regression and the high prevalence of the infection in the general population, prospective and masked clinical trials are necessary to confirm that treatment for HP infection may benefit patients with CCSC. Such a suggestion was previously made by Abreu et al. in 2008 in their reply (29).

AUTHOR CONTRIBUTIONS

Casella AM conducted the study and was involved in its design, data collection, analysis, interpretation, and management, review and approval of the manuscript. Berbel RF, Bressanim GL, Malaguido MR, and Cardillo JA conducted the study, were involved in data collection and performed the data analysis, management and interpretation. Berbel RF was involved in the preparation, review, and approval of the manuscript.




Figure 3 - A patient with a six-month history of CSC and macular serous detachment (A-B). Fluorescein angiography showed RPE changes and a juxtafoveal leak (arrow), precluding regular laser treatment (C-D). The serous detachment improved after anti-HP treatment (E-F), and fluorescein angiography showed prominent resolution of the leakage with persistence of the RPE changes (G-H).




Figure 4 - A patient with a three-month history of recurrent CSC. Fundoscopy and OCT revealed serous detachment in the macular area (A-B). Fluorescein angiography showed a parafoveal leak in the papillomacular bundle (C-D). The serous detachment and the leak were both resolved after anti-HP treatment (E-H).

REFERENCES

1. Tittl MK, Spaide RF, Wong D, Pilotto E, Yannuzzi LA, Fisher YL, et al. Systemic and ocular findings in central serous chorioretinopathy. *Am J Ophthalmol*. 1999;128(1):63-8, [http://dx.doi.org/10.1016/S0002-9394\(99\)00075-6](http://dx.doi.org/10.1016/S0002-9394(99)00075-6).
2. Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S. Risk factors for central serous chorioretinopathy: a case-control study. *Ophthalmology*. 2004;111(20):244-9, <http://dx.doi.org/10.1016/j.ophtha.2003.09.024>.
3. Guyer DR, Gargoudas ES. Central Serous Chorioretinopathy. In: Albert DM, Jakobiec FA. *Principles and Practice of Ophthalmology*. Philadelphia: Saunders, 1994;818-25.
4. Spaide RF, Campeas L, Haas A, Yannuzzi LA, Fisher YL, Guyer DR, et al. Central serous chorioretinopathy in younger and older adults. *Ophthalmology*. 1996;103(12):2070-80.
5. Yannuzzi LA, Slakter JS, Gross NE, Spaide RF, Costa DL, Huang SJ, et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot Study. *Retina*. 2003;23(3):288-98, <http://dx.doi.org/10.1097/00006982-200306000-00002>.
6. Carvalho-Recchia CA, Yannuzzi LA, Negrão S, Spaide RF, Freund KB, Rodriguez-Coleman H, et al. Corticosteroids and central serous chorioretinopathy. *Ophthalmology*. 2002;109(1):1834-7, [http://dx.doi.org/10.1016/S0161-6420\(02\)01117-X](http://dx.doi.org/10.1016/S0161-6420(02)01117-X).
7. Koyama M, Mizota A, Igarashi Y, Adachi-Usami E. Seventeen cases of central serous chorioretinopathy associated with systemic corticosteroid therapy. *Ophthalmologica*. 2004;218(2):107-10, <http://dx.doi.org/10.1159/000076145>.
8. Michael JC, Pak J, Pulido J, de Venecia G. Central serous chorioretinopathy associated with administration of sympathomimetic agents. *Am J Ophthalmol*. 2003;136(1):182-5, [http://dx.doi.org/10.1016/S0002-9394\(03\)00076-X](http://dx.doi.org/10.1016/S0002-9394(03)00076-X).
9. Giusti C. Central serous chorioretinopathy: a new extragastric manifestation of *Helicobacter pylori*? Analysis of a clinical case. *Clin Ter*. 2001;152(6):393-7.
10. Mauguet-Fayssse M, Kodjikian L, Quaranta M, Ben Ezra D, Trepsat C, Mion F, et al. Rôle de l'*Helicobacter pylori* dans la chorioretinopathie séreuse centrale et l'épithéliopathie rétinienne diffuse. Résultats de la première étude prospective pilote. *J Fr Ophtalmol*. 2002;25(10):1021-5.
11. Ahnoux-Zabsonre A, Quaranta M, Mauguet-Fayssse M. Prévalence de l'*Helicobacter pylori* dans la chorioretinopathie séreuse centrale et l'épithéliopathie rétinienne diffuse. *J Fr Ophtalmol*. 2004;27(10):1129-33, [http://dx.doi.org/10.1016/S0181-5512\(04\)96281-X](http://dx.doi.org/10.1016/S0181-5512(04)96281-X).
12. Asensio-Sánchez VM, Rodríguez-Delgado B, García-Herrero E, Cabo-Vaquera V, García-Loygorri C. Coriorretinopatía serosa central como manifestación extradigestiva de infección gástrica por *Helicobacter pylori*. *Arch Soc Esp Oftalmol*. 2008;83(3):177-82.
13. Giusti C. Association of *Helicobacter pylori* with central serous chorioretinopathy: hypotheses regarding pathogenesis. *Med Hypotheses*. 2004;63(3):524-7, <http://dx.doi.org/10.1016/j.mehy.2004.02.020>.
14. Cotticelli L, Borrelli M, D'Alessio AC, Menzione M, Villani A, Piccolo G, et al. Central serous chorioretinopathy and *Helicobacter pylori*. *European journal of ophthalmology*. 2006;16(2):274-8.
15. Misiuk-Hojło M, Michałowska M, Turno-Krecicka A. *Helicobacter pylori*--a risk factor for the development of the central serous chorioretinopathy. *Klin Oczna*. 2009;111(1-3):30-2.
16. Rahbani-Nobar MB, Javadzadeh A, Ghojzadeh L, Rafeey M, Ghorbanihaghjo A. The effect of *Helicobacter pylori* treatment on remission of idiopathic central serous chorioretinopathy. *Mol Vis*. 2011;17:99-103.

17. Ogata SK, Kawakami E, Patrício FRS, Pedroso MZ, Santos AM. Evolution of invasive and non-invasive methods for the diagnosis of *Helicobacter pylori* in symptomatic children and adolescents. *São Paulo Med J*. 2001;119(2):67-71, <http://dx.doi.org/10.1590/S1516-31802001000200006>.
18. Santos IS, Boccio J, Santos AS, Valle NC, Halal CS, Bachilli MC, et al. Prevalence of *Helicobacter pylori* infection and associated factors among adults in Southern Brazil: a population-based cross-sectional study. *BMC Public Health*. 2005;5:118, <http://dx.doi.org/10.1186/1471-2458-5-118>.
19. Zaterka S, Eisig JN, Chinzon D, Rothstein W. Factors related to *Helicobacter pylori* prevalence in an adult population in Brazil. *Helicobacter*. 2007;12(1):82-8.
20. Mitchell HM. The epidemiology of *Helicobacter pylori*. *Curr Top Microbiol Immunol*. 1999;241:11-30, http://dx.doi.org/10.1007/978-3-642-60013-5_2.
21. D'Elia MM, Andersen LP. *Helicobacter pylori*: Inflammation, Immunity, and Vaccines. *Helicobacter*. 2007;12(Suppl.1):15-9, <http://dx.doi.org/10.1111/j.1523-5378.2007.00530.x>.
22. Maeda S, Mentis AF. Pathogenesis of *Helicobacter pylori* Infection. *Helicobacter*. 2007;12 (Suppl.1):10-4.
23. Bohr URM, Annibale B, Franceschi F, Roccarina D, Gasbarrini A. Extragastric Manifestations of *Helicobacter pylori* Infection – Other *Helicobacters*. *Helicobacter*. 2007;12(Suppl. 1):45-53.
24. Whittle BJR, Morschl E, Pozsár J, Moran AP, László F. *Helicobacter pylori* lipopolysaccharide provokes iNOS-mediated acute systemic microvascular inflammatory responses in rat cardiac, hepatic, renal and pulmonary tissues. *J Physiol Paris*. 2001;95(1-6):257-9, [http://dx.doi.org/10.1016/S0928-4257\(01\)00035-3](http://dx.doi.org/10.1016/S0928-4257(01)00035-3).
25. Giusti C, Mauget-Faÿsse M. *Helicobacter pylori* and idiopathic central serous chorioretinopathy. *Swiss Med Wkly*. 2004;134(27-28):395-8.
26. Ushima H, Echizen H, Nachi S, Ohnishi A. Dose-dependent inhibition of CYP3A activity by clarithromycin during *Helicobacter pylori* eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol. *Clin Pharmacol Ther*. 2002;72(1):33-43, <http://dx.doi.org/10.1067/mcp.2002.125559>.
27. Mansuetta CC, Mason JO 3rd, Swanner J, Feist RM, White MF Jr, Thomley ML, et al. An association between central serous chorioretinopathy and gastroesophageal reflux disease. *Am J Ophthalmol*. 2004;137(6):1096-100, <http://dx.doi.org/10.1016/j.ajo.2004.01.054>.
28. Aggio FB, Roisman L, Melo GB, Lavinsky D, Cardillo JA, Farah ME. Clinical factors related to the visual outcome in central serous chorioretinopathy. *Retina*. 2010;30(7):128-34.
29. Abreu R, Nadal J, Abreu P. *Helicobacter pylori* and central serous chorioretinopathy. *Arch Soc Esp Oftalmol*. 2008;83(11):637-8.